B.1.617 variant of SARS-CoV-2 drove surge in the COVID-19 cases in last 2 months

According to INSACOG, the B.1.1.7 lineage of the virus, which was first identified in the United Kingdom, is declining in proportion across India in the last one and half month

June 04, 2021 06:44 pm | Updated 06:58 pm IST - New Delhi

So far, four Variants of Concern (voc) have been identified by the WHO: B.1.1.7, B.1.351, P2 and B.1.617.2

So far, four Variants of Concern (voc) have been identified by the WHO: B.1.1.7, B.1.351, P2 and B.1.617.2

The surge of COVID-19 cases in the country in the last two months shows a correlation with the rise in B.1.617 variant of the SARS-CoV-2, according to INSACOG, a grouping of 10 national laboratories.

April and May witnessed a deadly second wave of coronavirus cases that swept through the country stretching the healthcare infrastructure to its limits.

According to INSACOG, the B.1.1.7 lineage of the virus, which was first identified in the United Kingdom is declining in proportion across India in the last one and half month. The B.1.1.7 variant of the coronavirus has been named ‘Alpha’.

The B.1.617 lineage of SARS CoV-2 was first reported from Maharashtra but it is now seen in other states such as West Bengal, Andhra Pradesh, Delhi, Gujarat, Telangana.

“The current surge in cases seen over the last two months in some states shows a correlation with the rise in the B.1.617 lineage of SARS CoV-2,” the Indian SARS-CoV-2 Consortium on Genomics (INSACOG) said.

The B.1.617 lineage has further evolved into three sublineages – B.1.617.1, B.1.617.2 and B.1.617.3. Early data shows B.1.617.2, dubbed as Delta by WHO, has higher transmission advantages over the other two sub-lineages.

B.1.617, initially termed as double mutant, has three new spike protein mutations. Two mutations -- E484Q and L452R -- are in the area important for antibody-based neutralisation. The third mutation -- P681R in B.1.617 -- along with the reversion of E484Q allows its sub-lineage to be more infectious.

The World Health Organisation (WHO) has termed it as ‘Variant of Concern’.

B.1.617.1 and B.1.617.3 sub-lineages have two receptor binding domain mutations — L452R and E484Q. The former has seven spike mutation while the latter has seven to eight.

In the case of B.1.617.3, it has nine to 10 spike mutations and two receptor binding domain mutations — L452R and T478K.

In the case of all the three sub-lineage, it has the potential to reduced antibody efficacy and potential reduced neutralisation by vaccine sera, which, however, remains to be established.

The Indian SARS-CoV-2 Consortium on Genomics (INSACOG) is a grouping of 10 National Laboratories that was established by the Ministry of Health and Family Welfare on December 25 last year.

It has been carrying out genomic sequencing and analysis of COVID-19 viruses and correlating epidemiological trends with genomic variants.

Genomic variants of various viruses are a natural phenomenon and are found in almost all countries.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.